Substance / Medication

Bezlotoxumab

Overview

Active Ingredient
bezlotoxumab
RxNorm CUI
1855048

Indications

Clostridioides difficile ZINPLAVA™ is indicated to reduce recurrence ofinfection (CDI) in adults and pediatric patients 1 year of age and older who are receiving antibacterial drug treatment for CDI and are at a high risk for CDI recurrence.

Labeler: Merck Sharp & Dohme LLCUpdated: 2024-11-12T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

1
Total Trials
0
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy, Safety, and Cost-effectiveness of Bezlotoxumab in Preventing Recurrent Clostridioides difficile Infection : Systematic Review and Meta-analysis.
Mohamed Mouhand F H, Ward Christopher, Beran Azizullah et al. · J Clin Gastroenterol · 2024
PMID: 37395627Meta-Analysis
A randomized controlled trial of precision bezlotoxumab treatment for Clostridioides difficile infection.
Psarrakis Christos, Tziolos Nikolaos-Renatos, Matzarakis Vicky et al. · Cell Rep Med · 2026
PMID: 41483804RCT
Efficacy of Bezlotoxumab in Trial Participants Infected With Clostridioides difficile Strain BI Associated With Poor Outcomes.
Johnson Stuart, Citron Diane M, Gerding Dale N et al. · Clin Infect Dis · 2021
PMID: 32735653RCT
Bezlotoxumab as Treatment for Recurrent/Chronic Clostridioides difficile Infection in Pediatric Stem Cell Transplant Recipients: A Multi-Institutional Experience.
Fan Aaron E, Alqahtani Shaikha, Garnes Natalie Dailey et al. · Pediatr Blood Cancer · 2025
PMID: 40879561Observational
Bezlotoxumab during the first episode of Clostridioides difficile infection in patients at high risk of recurrence.
Escudero-Sanchez Rosa, Ramos-Martínez Antonio, Caballero-Bermejo Antonio F et al. · Eur J Clin Microbiol Infect Dis · 2024
PMID: 38236366Observational
Efficacy of bezlotoxumab in preventing the recurrence of Clostridioides difficile infection: an Italian multicenter cohort study.
Meschiari Marianna, Cozzi-Lepri Alessandro, Cervo Adriana et al. · Int J Infect Dis · 2023
PMID: 37030653Observational
The effect of bezlotoxumab for prevention of recurrent Clostridium difficile infection (CDI) in Japanese patients.
Mikamo Hiroshige, Aoyama Norihiro, Sawata Miyuki et al. · J Infect Chemother · 2018
PMID: 29097028Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Bezlotoxumab (substance)
SNOMED CT
723524001
UMLS CUI
C4291320
RxNorm CUI
1855048
Labeler
Merck Sharp & Dohme LLC

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
1
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.